The Summit Score Stratifies Mortality and Morbidity in Chronic Obstructive Pulmonary Disease
Benjamin D Horne1,2, Matthew J Hegewald3, Courtney Crim4
1Intermountain Medical Center Heart Institute, Salt Lake City, UT, USA.
Summary
The Summit Score effectively predicts mortality in chronic obstructive pulmonary disease (COPD) patients with cardiovascular risks. It also identified a subgroup benefiting from fluticasone furoate/vilanterol treatment.
Area of Science:
- Pulmonary Medicine
- Cardiovascular Medicine
- Clinical Epidemiology
Background:
- Chronic obstructive pulmonary disease (COPD) frequently co-occurs with cardiovascular risk factors.
- Predicting mortality in COPD patients with comorbidities is crucial for effective management.
Purpose of the Study:
- To derive and validate the Summit Score for predicting all-cause mortality in COPD patients.
- To assess the score's utility in identifying COPD subpopulations that may benefit from specific inhaled corticosteroid/long-acting beta-agonist treatments.
Main Methods:
- The Summit Score was developed using data from 16,485 subjects in the SUMMIT trial (derivation and internal validation cohorts).
- External validation was performed on three independent COPD cohorts from Intermountain Healthcare (N=45,972), including patients with and without cardiovascular risks.
- Cox regression analysis identified 13 key predictors of mortality.
Main Results:
- The Summit Score demonstrated good predictive performance across all validation cohorts (c-statistics ranging from 0.662 to 0.736).
- Higher Summit Score quartiles were associated with significantly increased mortality risk (e.g., HR=4.43 in SUMMIT validation, HR=8.15 in Intermountain cardiovascular risk outpatients).
- In a post hoc analysis, fluticasone furoate (FF) 100μg/vilanterol (VI) 25μg treatment showed a mortality benefit (HR=0.76) compared to placebo in patients with Summit Scores of 14-19.
Conclusions:
- The Summit Score is a validated tool for predicting mortality in diverse COPD populations.
- The score can help identify COPD patients who may respond favorably to FF 100μg/VI 25μg therapy, suggesting a personalized treatment approach.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.9K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.9K
01:22Chronic Obstructive Pulmonary Disease
2.0K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.0K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.4K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.4K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.9K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.9K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.0K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.3K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.3K